



Cite this: *Mater. Adv.*, 2022,
3, 4707

Dual CEA/CD44 targeting to colorectal cancer cells using nanobody-conjugated hyaluronic acid-modified mesoporous silica nanoparticles with pH- and redox-sensitivity

Xiying Fan,^a Tingting Wang,^a Min Han,^b Yi Gu,^{ac} Guochuan Sun,^a Xinying Peng,^{ac} Qinghui Shou,^a Haipeng Song,^d Wenshuai Liu^{*a} and Rui Nian^{id} ^{*a}

Colorectal cancer (CRC) is the second leading cause of cancer death among all malignancies. Drug delivery targeting tumor surface receptors improve therapeutic effects and lower side-effects since they can increase the drug accumulation in target tissues and cellular uptake. In this study, we established a pH- and redox-responsive drug delivery system based on mesoporous silica nanoparticles (MSNs) for the delivery of the anticancer drug doxorubicin hydrochloride (DOX). In this drug delivery system, MSNs-NH₂ were modified with hyaluronic acid (HA) to form a highly loaded anticancer drug core; they were further coated with 11C12, a nanobody against carcinoembryonic antigen (CEA) to form a guiding outer layer (DOX@MSNs-HA-11C12). The accurate localization of nanoparticles would be mediated by two targeting molecules HA and nanobody 11C12, which target the CD44 receptor and the proximal membrane end of CEA on the surface of CRC cells, respectively. The release amount of DOX observed from *in vitro* drug release profiles increased as follows: pH 7.4 < pH 6.8 < pH 5.4, and (pH 7.4 + GSH) < (pH 6.8 + GSH) < (pH 5.4 + GSH), illustrating that the drug release could be accelerated in a weakly acidic environment as well as in the presence of reduced glutathione (GSH). *In vitro* cytotoxicity experiments showed that MSNs-HA-11C12 nanoparticles exhibited good biocompatibility and safety. Drug loaded nanoparticles modified by dual targeting molecules HA and 11C12 (DOX@MSNs-HA-11C12) led to higher LoVo CRC cell apoptosis *in vitro*, compared with DOX@MSNs-NH₂ and DOX@MSNs-HA. Confocal laser scanning microscopy and fluorescence spectrophotometry further confirmed that the dual-targeting system significantly enhanced the uptake of DOX@MSNs-HA-11C12 by LoVo cells and the internalization of DOX was the highest, followed by DOX@MSNs-HA, DOX@MSNs-NH₂, and DOX, subsequently. In this study, the nanobody targeting CEA was combined with the HA targeting CD44 receptor for the first time, which proved that the dual CEA/CD44 formulation can promote a more accurate drug delivery mode for CRC cells, and provide a basis for subsequent drug development for treating CRC and related cancers.

Received 25th January 2022,
Accepted 23rd April 2022

DOI: 10.1039/d2ma00082b

rsc.li/materials-advances

1. Introduction

Colorectal cancer (CRC) is a heterogeneous disease, which is mainly caused by precancerous polyps including traditional

tubular adenomas and serrated polyps, and develops through the gradual accumulation of distinctive genetic and epigenetic alterations.¹ Global cancer statistics for 2020 showed that CRC was the third most frequently diagnosed cancer and the second leading cause of cancer death among all malignancies.² To date, the main treatments for CRC include surgery, chemotherapy, radiotherapy, biological immunity, and surgery combined with adjuvant chemotherapy. However, 86% of CRC patients die within 5 years after diagnosis due to the complex pathogenesis, poor solubility, and a large number of toxic side effects of chemotherapeutic drugs.³ Thus, considerable efforts have to be made to find effective treatments for CRC. To expand the therapeutic window, more efforts have been devoted to alternative therapies, including antibody-mediated targeted

^a CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, No. 189 Songling Road, Qingdao 266101, China. E-mail: liuws@qibebt.ac.cn, nianrui@qibebt.ac.cn

^b Department of Stomatology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, No. 16766 Jingshi Road, Jinan 250101, China

^c University of Chinese Academy of Sciences, No. 19(A) Yuquan Road, Beijing 100049, China

^d Shenzhen Innova Nanobodi Co., Ltd, No. 1301 Guangguang Road, Shenzhen 518110, China

therapy, which has attracted great attention in the research of antitumor drugs because it can precisely clear cancer cells without damaging normal tissues.⁴ At the same time, the application of nanotechnology in a targeted drug delivery system (DDS) also plays a crucial role in improving cancer treatment.

Due to the large surface area and pore volume, tunable pore structures, thermal stability, and high biocompatibility, mesoporous silica nanoparticles (MSNs) can serve as efficient carriers for various therapeutic agents.⁵ Moreover, surface modifications of MSNs with tumor-targeting ligands (*e.g.* antibodies, polysaccharides, peptides, nucleic acids, and small molecules) further realize the controllable and efficient delivery of MSNs as drug carriers.^{6,7} In addition, the controlled release of loaded drugs from MSNs can be further significantly boosted by using switchable gatekeeper modifications sensitive to certain external stimuli, including pH, temperature, oxygen, and enzymes, making MSNs exhibit great advantages as drug carriers.^{6,8,9}

The preparation of DDS based on surface receptor recognition has attracted great attention. The common surface receptors of CRC include folate receptors, CD44 and carcinoembryonic antigen (CEA). CD44 is a common transmembrane glycoprotein in various cancer cells,¹⁰ and is particularly overexpressed in some types of colon cancers.¹¹ Hyaluronic acid (HA), a disaccharide unit glycosaminoglycan composed of D-glucuronic acid and N-acetylglucosamine, exhibits a high-affinity for CD44¹² and is reported as an excellent ligand for targeting CD44.¹³ Notably, although CD44 is also widely expressed in normal cells and tissues,¹⁴ partially weakening its specificity as a tumor target, CD44 on the surface of normal cells is in a resting state and cannot bind to HA, while CD44 on the surface of tumor cells is in an activated state and can bind to HA.¹⁵ Moreover, HA on the surfaces of MSNs enhances the dispersity of MSNs, which can be ascribed to two aspects: the electrostatic repulsions among the stretched hydrophilic HA chains and the steric hindrance among nanoparticles.¹⁶ Therefore, HA as a ligand attached to the surface of MSNs not only improves the dispersity and stability of MSNs, but also endows MSNs with the ability to target CD44 on CRC cells.

Serum levels of CEA is one of the most meaningful tumor markers in the diagnosis of CRC and is of great value in post-operative follow-up, surveillance, and for evaluating the effectiveness of surgery.¹⁷ More importantly, CEA was reported to be anchored on the surface of tumor cells *via* glycosylphosphatidylinositol (GPI). Thus, CEA-targeted drugs, especially antibody drugs, have shown great potential in the treatment of CRC. Bacac *et al.* found that a novel IgG-based T-cell bispecific antibody strongly targets not only to the tumor cells with high CEA expression, avoiding damage to primary epithelial cells with low-CEA expressing tumor, but also to CD3 epsilon chains expressed on T cells.¹⁸ The Lacava group developed maghemite nanoparticles modified by anti-CEA antibody that successfully targeted CRC cells expressing the CEA.¹⁹

Monoclonal antibodies (mAbs) play a crucial role in targeted drug delivery. Benefiting from its specific binding ability toward cell surface receptors, targeted drug delivery to a variety of tumors is achieved by coupling antibodies to nanoparticles

encapsulating small molecule chemotherapeutics, protein drugs, or nucleic acid based drugs.²⁰ As a representative of a new generation of genetically engineered antibodies, nanobodies are engineered from the variable domain of the camelid (or shark) heavy chain only antibodies.²¹ With a molecular weight of only 12–15 kDa, they are regarded as the smallest antigen-binding entities.^{22,23} In addition to a pair of canonical disulfide bonds that maintain the basic structure, nanobodies contain two pairs of atypical disulfide bonds between their framework regions 2, 4 (FR2, 4) and complementarity determining region 3 (CDR3), forming tighter folds and greatly improving protein stability. Furthermore, the CDR3 region of the nanobody is longer than that of conventional antibodies and further enhances the recognition of otherwise cryptic epitopes.²⁴ Meanwhile, the nanobody has a simple structure and is easily engineered into bivalent, multivalent as well as fusion forms by genetic engineering to exert more powerful biological functions. Compared to conventional antibodies, nanobodies can be manufactured to a high level in bacteria or yeast to significantly save on cost.²⁵ In our previous study, we screened and produced a pair of nanobodies, 11C12 and 2D5, that specifically bind CEA (dissociation constants of 12 nM and 774 pM, respectively).²⁶ They demonstrated superior specificity, with no binding to highly similar homologous proteins such as CEA-CAM1, 3, 6, 8 and fetoprotein, HE4 and CA125. They also exhibited exceptional stability. After storage in a high temperature and humidity environment (60 °C, 75% humidity) for 14 days, these nanobodies showed no degradation and no decrease in affinity. We have also developed a diagnosis kit for CEA based on these nanobodies, which can still accurately detect the content of CEA in clinical serum after storage at 37 °C and 50% relative humidity for 64 days.²⁶ More interestingly, the epitope prediction analysis showed that the binding site of 11C12 was in the near membrane region of CEA. Therefore, 11C12 has the potential to be used as a targeting antibody to modify nanoparticles and achieve drug targeted delivery.


In this study, MSNs-NH₂ were prepared using an organic template method. Doxorubicin hydrochloride (DOX) was loaded into the MSNs-NH₂ (DOX@MSNs-NH₂) *via* electrostatic adsorption (Scheme 1). Then, DOX@MSNs-NH₂ were functionalized by HA. Subsequently, nanobody 11C12 was connected to the surface of MSNs-HA to construct nanoparticles (DOX@MSNs-HA-11C12) with dual active targeting. The successful construction of MSNs-HA-11C12 was characterized by different measurement methods, including scanning electron microscopy (SEM), dynamic laser light scattering (DLS), Fourier transform infrared (FTIR) and thermogravimetric analysis (TGA). Furthermore, the release of DOX from nanoparticles was evaluated *in vitro*. The *in vitro* cellular cytotoxicity and cellular uptake of nanoparticles were evaluated as well.

2. Materials and methods

2.1. Materials and cell lines

Cetyltrimethylammonium bromide (CTAB) and tetraethyl orthosilicate were obtained from Tianjin Bodi Chemical





Scheme 1 Schematic illustration of DOX@MSNs-HA-11C12.

Holding Co., Ltd (Tianjin, China); polyethylene glycol, absolute ethanol and ethylene glycol (EG) were obtained from Sino-pharm Chemical Reagent Co., Ltd (Shanghai, China); cell counting kit-8 (CCK-8), 4',6-diamidino-2-phenylindole (DAPI), and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (Darmstadt, Germany). Phosphate-buffered saline (PBS) solution was purchased from Solarbio (Beijing, China). DOX and aminopropyltriethoxysilane (APTES) were obtained from Shanghai Aladdin Biochemical Technology Co., Ltd (Shanghai, China). HA was purchased from Beijing Mreda Technology Co., Ltd (Beijing, China). LoVo cells were obtained from Yuchi cell Biological Technology Co., Ltd (Shanghai, China). The BCA kit was purchased from Tiangen Biotech Co., Ltd (Beijing, China). All of the other chemicals were of analytical grade and were used as received.

2.2. Preparation of MSNs-NH₂

The MSNs-NH₂ were synthesized according to the previously published methods²⁷ and modified appropriately. 1.17 g CTAB was dissolved in a mixed solution containing 180 mL water, 30 mL EG, and 7.2 mL ammonia aqueous solution. After vigorous stirring at 600 rpm in a 50 °C water bath for 30 min, 4 mL TEOS and 0.74 mL APTES were rapidly added to the mixture. The final molar composition in the solution was 1 TEOS:0.18 APS:0.18 CTAB:4.7 NH₃:10 EG:558.1 H₂O. The resulting mixture was stirred for another 2 h at 50 °C and was then kept statically at the same temperature for 20 h. After reaction, sediment was collected by centrifugation at 14 000 rpm for 20 min, and redispersed with deionized water and absolute ethanol three times alternately. The sediment was vacuum dried at 60 °C overnight to obtain MSNs-NH₂.

In order to obtain the mesoporous structure, the organic template CTAB was removed using an ion exchange method.²⁸

1 g MSN-NH₂ was dispersed in ethanol (95%) containing 0.2 g NH₄Cl, and the mixture was stirred at 60 °C for 15 min, then the sediment was collected by centrifugation and washed with cold ethanol three times. The sediment was vacuum dried at 60 °C overnight to obtain MSNs-NH₂ with a mesoporous structure.

2.3. Conjugation of HA to MSNs-NH₂

Hydrophilic HA modified MSNs-NH₂ improve the dispersion of mesoporous silicon in PBS. HA (60 kDa) was first dissolved in water. The pH of the solution was adjusted by 0.1 M NaOH or 0.1 M HCl to 4.7–6.0, and then 1-(3-dimethylaminopropyl)-3-ethylcarbo-diimide/*N*-hydroxysuccinimide (EDC/NHS) was added for activation for 1 h. Ultrasonically dispersed MSNs-NH₂ suspension was added to the mixture. Subsequently, the pH of the mixture was adjusted to 7–8, and the mixture was stirred overnight at room temperature; thus the carboxyl group of HA reacts with the amino group of mesoporous silicon to realize the covalent connection, resulting in the carboxyl group being modified on MSNs-NH₂. After the reaction, the sample was centrifuged, and the precipitation was washed twice with deionized water, and finally centrifuged, precipitated, and lyophilized to obtain MSNs-HA.

2.4. Conjugation of nanobody 11C12 to MSNs-HA

Pegylation nanobody 11C12 was obtained according to the following steps. Firstly, the nanobody 11C12 stored in our laboratory was exchanged into PBS (pH 8.0), then 2 mg mL⁻¹ Traut's reagent was added and incubated at room temperature for 1 h (the molar ratio of Traut's reagent:nanobody was 40:1). The thiolated nanobody 11C12 was purified using an ultrafiltration tube and exchanged into PBS (pH 6.8). Then, 300 µL 20 mM NH₂-PEG₄-MAL was added, and the reaction was protected from light overnight under a nitrogen atmosphere.



After the reaction, $\text{NH}_2\text{-PEG}_4\text{-11C12}$ was purified using an ultrafiltration tube and exchanged into PBS (pH 7.4).

16 mg MSNs-HA was dispersed uniformly in 4 mL PBS (pH 5.4) by sonication. EDC (1.6 mg)/NHS (1.6 mg) was added and then stirred at room temperature to activate the carboxyl group for 1 h. The pH of the mixture was adjusted to 7–8. Then, $\text{NH}_2\text{-PEG}_4\text{-11C12}$ was added to the mixture. The mass ratio of the MSNs-HA to nanobody 11C12 was about 20 : 1. The reaction was processed as above at 4 °C overnight. After the reaction, the samples were separated by centrifugation, and the sediment was washed twice with PBS (pH 7.4) and the supernatant was retained. The initial concentration and the supernatant of 11C12 were determined using the BCA kit according to the manufacturer's method. The conjugation efficiency of 11C12 to MSNs-HA was determined indirectly.

2.5. Drug loading and stimuli-responsive drug release

The MSNs- NH_2 were dispersed into 2 mL PBS (pH 7.4) and then 2 mL 2 mg mL^{-1} DOX solution was added with stirring at room temperature for 24 h without light. After the reaction, the samples were separated by centrifugation. The sediment was washed twice with PBS (pH 7.4) and the supernatant was retained. Above the sediment was DOX@MSNs- NH_2 , for subsequent modification with HA and 11C12. Drug loading on nanoparticles was measured using UV-visible spectroscopy at 480 nm. The DOX entrapment efficiency (EE) and drug loading (DL) were calculated according to the following formula.

$$\text{EE} = \frac{(W_0 - W_1)}{W_0} \times 100\% \quad (1)$$

$$\text{DL} = \left(\frac{W_0 - W_1}{W_{\text{NP}}} \right) \times 100\% \quad (2)$$

where W_0 is the initial weight of DOX, W_1 is the weight of unloaded DOX, and W_{NP} is the weight of DOX@MSNs-HA-11C12.

To investigate the release of DOX in response to pH and redox dual-stimuli, DOX@MSNs-HA-11C12 were dispersed in 2 mL PBS at different pH values of 5.4, 6.8 and 7.4 with or without 10 mM GSH, respectively. Meanwhile, DOX@MSNs- NH_2 and DOX@MSNs-HA were incubated in 2 mL PBS (pH 7.4), respectively. The DOX released from DOX@MSNs- NH_2 , DOX@MSNs-HA, and DOX@MSNs-HA-11C12 was investigated at room temperature for 96 h. At a predetermined time, the supernatant was collected by centrifugation for quantitative analysis and replenished with the same volume of fresh medium. The absorbance of the supernatant was measured at 480 nm to calculate the cumulative DOX release.

2.6. Characterization of nanoparticles

2.6.1. Zeta potential. The Zeta potential of MSNs- NH_2 , MSNs-HA, MSNs-HA-11C12, and DOX@MSNs-HA-11C12 was measured by using DLS (Zetasizer NanoZS, Malvern Instruments Ltd, UK). All measurements were performed in triplicate at a scattering angle of 92° and temperature of 25 °C after adequate dilution with purified water.

2.6.2. TEM. The morphological characteristics of MSNs- NH_2 , MSNs-HA, and MSNs-HA-11C12 were observed using TEM. The prepared samples were ultrasonically dispersed in absolute ethanol and mounted on carbon film-coated copper grids, dried naturally, and then TEM images were captured using transmission electron microscopy JEM-2100F (Hitachi, Tokyo, Japan).

2.6.3. Dispersity and stability of MSNs- NH_2 , MSNs-HA, and MSNs-HA-11C12. In order to explore the dispersibility and stability of MSNs- NH_2 , MSNs-HA, and MSNs-HA-11C12, the same amount of nanoparticles were weighed and suspended in the same volume of PBS (pH 7.4). The states of the nanoparticles were observed and photographed at a predetermined time.

2.6.4. N_2 adsorption-desorption isotherms. The surface area and pore size of the samples were measured by N_2 adsorption-desorption isotherms via a Micromeritics Tristar 3020. The samples were dried in advance to prevent the interference of moisture. About 0.2 g of the samples were placed in the desorption tube for vacuum desorption overnight to remove the adsorbed impurity. Then, the desorption tube was placed in a physical adsorption instrument to carry out a N_2 adsorption-desorption experiment at −196 °C under continuous adsorption conditions.

2.6.5. FTIR measurement. The FTIR spectrum of the samples was recorded on a Fourier transform infrared spectrophotometer (Nicolet 6700 FTIR Spectrometer, Thermo Fisher, USA) at room temperature following the method of Zixian *et al.*²⁹ FTIR spectra were obtained from discs containing 2 mg of samples in approximately 100 mg of potassium bromide with the frequency range from 4000 to 400 cm^{-1} at a data acquisition rate of 2 cm^{-1} per point.

2.6.6. TGA. 5 mg of samples were weighted and hermetically sealed in aluminum pans. The weight profiles of the samples were assessed using an STA 449F5 instrument (Netzsch, Germany) from room temperature to 800 °C at a heating rate of 10 °C per min under a N_2 atmosphere.

2.7. In vitro cytotoxicity evaluation

In vitro cellular cytotoxicity of free DOX, DOX@MSNs- NH_2 , DOX@MSNs-HA, DOX@MSNs-HA + free HA, and DOX@MSNs-HA-11C12 was evaluated by CCK8 assay. The LoVo cells in the logarithmic growth period were inoculated into 96-well plates with 10 000 LoVo cells per well, and cultured in a 5% CO_2 cell incubator. The culture medium in the well was discarded after 24 h. 100 μL of cell culture medium containing different concentrations of DOX loaded nanoparticles was added to each well. Free DOX was used as a positive control. After incubation for 48 h at 37 °C, the medium was removed, and fresh PBS was used to rinse the well three times. Then, 100 μL cell culture medium containing 10 μL CCK8 was added to each well. After incubation for 2 h at 37 °C, the absorbance was measured on a microplate reader at a double wavelength of 450 nm and 630 nm. Cell viability was calculated based on the reading.



2.8. *In vitro* cellular uptake

Confocal laser scanning microscopy (CLSM) assessed the internalization extent of DOX from free DOX, DOX@MSNs-NH₂, DOX@MSNs-HA, and DOX@MSNs-HA-11C12 into LoVo cells. LoVo cells were seeded into 24-well plates at a density of 5×10^5 per well and incubated overnight. Then, the cells were treated with either 20 $\mu\text{g mL}^{-1}$ free DOX or nanoparticles containing 20 $\mu\text{g mL}^{-1}$ DOX. After incubation for 2 h in a 5% CO₂ incubator at 37 °C, LoVo cells were washed with PBS three times and stained with 100 μL DAPI for 5–10 min. Subsequently, the cells were washed with cold PBS three times. Finally, the cells were soaked in PBS and stored away from light. The cells were visualized under CLSM with the following channels: DAPI is blue light, DOX is red light.

The uptake of free DOX, DOX@MSNs-NH₂, DOX@MSNs-HA, and DOX@MSNs-HA-11C12 was determined using a fluorescence spectrophotometer. LoVo cells were seeded in 6-well plates at a density of 5×10^5 per well and incubated overnight. Then, the cells were treated with either 20 $\mu\text{g mL}^{-1}$ free DOX or nanoparticles containing 20 $\mu\text{g mL}^{-1}$ DOX. The LoVo cells were cultured in a 5% CO₂ incubator at 37 °C for 1 h, 2 h, and 4 h, the medium was discarded, and then the LoVo cells were washed with PBS three times. Trypsin was added to each well to digest the LoVo cells. After centrifugation at 1000 rpm for 5 min, the sediment was resuspended in PBS and washed two times. Then, cell lysate was added to lyse the cells. The fluorescence intensity at 480 nm excitation/590 nm emission wavelength was measured using a fluorescence spectrophotometer.

2.9. Statistical analysis

Each experiment was performed independently and in triplicate. All experimental data were presented as mean $\pm$ SD

(standard deviation). Differences in means were tested using Duncan's tests, and *P*-values below 0.05 were considered significant.

3. Results and discussion

3.1. Synthesis of DOX@MSNs-HA-11C12

The design and synthetic strategy of DOX@MSNs-HA-11C12 are illustrated in Scheme 1 and the procedure consists of four steps. Firstly, MSNs-NH₂ were synthesized and modified according to the published methods.²⁷ Under alkaline conditions, amino modified MSNs were synthesized in one-step with precursor tetraethoxysilane (TEOS) as raw materials. Then, DOX was loaded into the MSNs-NH₂ *via* electrostatic adsorption. Thereafter, HA functionalized DOX@MSNs-NH₂ were prepared based on HA specific binding CD44 receptors which were abundantly expressed on CRC cells.^{11,15} Finally, owing to the specific binding of nanobody 11C12 to the near membrane end of CEA on the surface of CRC cells, nanobody 11C12 was connected to the surface of DOX@MSNs-HA to construct nanoparticles with dual active targeting.

3.2. Characterization of nanoparticles

The average diameter of MSNs-NH₂ shown in the TEM images was 144.9 ± 5.2 nm (Fig. 1A). After modification of HA and nanobody 11C12, the average particle sizes of MSNs-HA and MSNs-HA-11C12 had barely changed (Fig. 1C and D). Meanwhile, the surface morphologies of MSNs-NH₂, MSNs-HA, and MSNs-HA-11C12 showed obvious differences (Fig. 1A–D). The surface of MSNs-NH₂ was evenly distributed with small pits and pores, exhibiting a highly ordered state (Fig. 1A and B). After modification of HA, the outer layer of MSNs was uniformly encapsulated by HA, and the surface of the entire MSNs-HA




Fig. 1 TEM images of (A) MSNs-NH₂, (B) MSNs-NH₂ with high resolution, (C) MSNs-HA, and (D) MSNs-HA-11C12. (E) Zeta potential of MSNs-NH₂, MSNs-HA, and MSNs-HA-11C12. Error bars and standard deviations from three independent experiments.



presented a rough coat with unclear mesopores (Fig. 1C). After coupling with nanobody 11C12, the surface of MSNs-HA-11C12 became rougher and formed convex entanglement (Fig. 1D).

Zeta potential is an important index used to characterize the stability of nanoparticles in a dispersion system through the electrostatic repulsion between the nanoparticles.³⁰ Zeta potential values of MSNs-NH₂, MSNs-HA, and MSNs-HA-11C12 were measured using DLS, and the data are displayed in Fig. 1E. The mean surface charge of MSNs-NH₂ was $+30.5 \pm 1.0$ mV. The positive zeta potential of MSNs-NH₂ is attributed to the presence of a large amount of positively charged amino groups on MSNs.³¹ For HA functionalized MSNs, the zeta potential of MSNs-HA decreased to -23.4 ± 1.1 mV, which meant that the carboxyl group of HA on the surface of MSNs became dominant, and the negative charge carried by it completely sheltered the positive charge of the amino group on the surface of MSNs, making the whole nanoparticle negatively charged. The surface modification with nanobody 11C12 increased the charge value to -22.3 ± 0.6 mV due to the nanobody 11C12 with a slightly positive charge. The isoelectric point (pI) of nanobody 11C12 was 9.21, and nanobody 11C12 was connected to the surface of MSNs-HA under PBS (pH 8.0); thus nanobody 11C12 had a positive charge. The results revealed MSNs-NH₂, MSNs-HA, and MSNs-HA-11C12 were constructed successfully according to our design.

As reported by many researchers, MSNs and MSNs-NH₂ agglomerated inevitably in saline and PBS. Therefore, they cannot be used directly for intravenous injection because the original charge balance between particles can be destroyed in blood circulation.^{16,32,33} In our research, MSNs-NH₂ were uniformly dispersed in PBS at the initial stage and agglomerated largely within 5 min. In contrast, HA modified MSNs-NH₂ and HA-11C12-dual modified MSNs-NH₂ greatly alleviated the agglomeration (Fig. 2). The dispersity improvement likely results from the electrostatic repulsion and steric hindrance among stretched hydrophilic HA chains.^{34,35} In addition, CD44-positive cancer cells endocytose MSNs-HA more effectively *via* a receptor-mediated endocytosis mechanism.³⁶ Besides, because of the high affinity and excellent solubility of nanobodies,

nanobody-derived nanoparticles demonstrated a high target specificity, high stability, and good solubility. Therefore, HA and 11C12 capping not only provided the MSNs-NH₂ with a more abundant biofunctionalized surface, but also effectively prevented the MSNs-NH₂ from aggregating in saline solutions.

The isotherms and pore size distribution curves of MSNs-NH₂, MSNs-HA, and DOX@MSNs-HA-11C12 were measured by N₂ adsorption-desorption test analysis as shown in Fig. 3A and B. Meanwhile, Table 1 lists the Brunauer-Emmett-Teller (BET) surface area, total pore volume, and pore size. For MSNs-NH₂, the BET surface area, pore volume, and pore size were $633 \text{ m}^2 \text{ g}^{-1}$, $0.85 \text{ cm}^3 \text{ g}^{-1}$, and 2.8 nm , respectively. After the modification of HA, the pore volume ($0.7 \text{ cm}^3 \text{ g}^{-1}$) and pore size (2.4 nm) of MSNs-HA were slightly decreased, which showed that the internal mesoporous network was not blocked by HA. After DOX loading (DOX@MSNs-HA-11C12), the BET surface area ($70 \text{ m}^2 \text{ g}^{-1}$), total pore volume ($0.18 \text{ cm}^3 \text{ g}^{-1}$), and pore size (about 0 nm) were sharply decreased, which indicated that DOX successfully entered the internal mesoporous network.

TGA curves of MSNs-NH₂, MSNs-HA, and MSNs-HA-11C12 are shown in Fig. 3C. The weight loss of bare MSNs-NH₂ was 19.38%. After surface functionalization of MSNs-NH₂ with HA and 11C12, the weight loss of MSNs-HA and MSNs-HA-11C12 increased to 26.67% and 29.35%, respectively, which illustrated that about 7.29% of HA and 2.68% of 11C12 were introduced onto the surface of MSNs-NH₂. According to the BCA assay, the amount of 11C12 was $24 \mu\text{g mg}^{-1}$ nanoparticles, which is consistent with the result of TGA. These results indicated that MSNs-HA and MSNs-HA-11C12 were successfully developed.

The surface conversion of the raw material and the prepared nanoparticles was evaluated using FTIR spectroscopy (Fig. 3D). In the spectrum of MSN-NH₂, the corresponding absorption peaks of the silica structure were observed, the stretching vibration of Si-O at $\sim 1100 \text{ cm}^{-1}$ and the bending vibration of Si-OH, Si-O-Si, and Si-O at $\sim 951 \text{ cm}^{-1}$, $\sim 800 \text{ cm}^{-1}$, and $\sim 464 \text{ cm}^{-1}$, respectively. The stretching vibration of C=O coming from HA appeared at $\sim 1406 \text{ cm}^{-1}$ after the conjugation of the MSN-NH₂ with HA. For MSNs-HA-11C12, new peaks of carbon associated stretching or bending vibration from




Fig. 2 Comparison of MSNs-NH₂ (left), MSNs-HA (middle), and MSNs-HA-11C12 (right) suspended in PBS (pH 7.4) for 0 min, 5 min, 1 h, 5 h, 24 h, 36 h, 48 h, and 72 h. The same amount of both nanoparticles was weighed and the same volume of PBS was then added. The particles were fully suspended by shaking as the starting point.






Fig. 3 (A) N₂ adsorption-desorption isotherms of MSNs-NH₂, MSNs-HA, and DOX@MSNs-HA-11C12. (B) Pore size distributions of MSNs-NH₂, MSNs-HA, and DOX@MSNs-HA-11C12. (C) TGA analysis of MSNs-NH₂, MSNs-HA and MSNs-HA-11C12. (D) FTIR spectra of MSNs-NH₂ (a), HA (b), MSNs-HA (c), 11C12 (d), and MSNs-HA-11C12 (e).

Table 1 The N₂ adsorption-desorption parameters of MSNs-NH₂, MSNs-HA, and DOX@MSNs-HA-11C12 nanoparticles

Sample	BET surface area (m ² g ⁻¹)	Pore volume (cm ³ g ⁻¹)	Pore size (nm)
MSNs-NH ₂	633	0.85	2.8
MSNs-HA	567	0.70	2.4
DOX@MSNs-HA-11C12	70	0.18	0

11C12 were shown from ~ 500 cm⁻¹ to 700 cm⁻¹. These results indicated the successful conjugation of the MSNs-NH₂ with HA and 11C12 in sequence.

3.3. DOX loading and *in vitro* DOX release kinetics

DOX, a cancer chemotherapeutic agent, was chosen as a guest model drug and loaded into the pores of MSNs-NH₂, MSNs-HA, and MSNs-HA-11C12. The EE of MSNs-NH₂, MSNs-HA, and MSNs-HA-11C12 were 88.36%, 82.37%, and 73.12%, respectively. The DL of MSNs-NH₂, MSNs-HA, and MSNs-HA-11C12 were 30.64%, 29.17%, and 26.77%, respectively. By comparison, it was found that the EE and DL of MSNs-HA-11C12 decreased slightly in that the loss of DOX occurred during HA and 11C12 modified MSNs-NH₂. Although MSNs have made great progress as nanocarriers, their low DL, which is generally less than 20%,^{6,34,37,38} has limited their applications. This dual targeting

MSNs based on HA and nanobody 11C12 achieved a relatively high drug loading efficiency up to 26.77%, which reduces the accumulation of foreign materials *in vivo* and enhances the safety of cancer treatment.

To investigate the pH and redox dual-stimuli responsive release of MSNs-HA-11C12, the DOX release studies were taken under different pH (7.4, 6.8 and 5.4) with or without GSH (Fig. 4). A typically biphasic release pattern was observed in all of the nanoparticles: an initial burst release of DOX in the first 5 h owing to partial DOX adsorbed on the surface of nanoparticles was rapidly dissolved and diffused into the medium; then a sustained drug release up to 96 h in that DOX loaded into the pores of nanoparticles slowly released outward. In order to simulate the accumulative drug release experiments of MSNs-NH₂, MSNs-HA, and MSNs-HA-11C12 under normal physiological conditions, the experiments were carried out in PBS (pH 7.4) at room temperature (Fig. 4A). The DOX release amount from MSNs-NH₂ reached 13.1% within 5 h and then increased to 19.53% in 96 h; meanwhile, 13.09% and 8.88% of DOX were released within 96 h from MSNs-HA and MSNs-HA-11C12, respectively. All the profiles present the initial rapid DOX release, followed by a fairly plateau stage afterwards. The result indicates that the drug delivery systems release drug slowly and are good vehicles for cancer treatment.

The cumulative DOX release was only 8.88% at pH 7.4 and 11.89% at pH 6.8, but reached as high as 49.27% at pH 5.4 as






Fig. 4 (A) *In vitro* drug release profiles of DOX@MSNs-NH₂, DOX@MSNs-HA, and DOX@MSNs-HA-11C12 in media with physiological pH. (B) *In vitro* drug release profile of DOX@MSNs-HA-11C12 in media with different pH values (pH 7.4, 6.8 and 5.4) and with GSH or not.

the DOX was rapidly released, indicating a pH responsive of the DOX release in this drug loaded system (Fig. 4B). This phenomenon mainly comes from the following two aspects: the DOX solubility was enhanced and electrostatic interaction between the DOX and nanoparticles was relatively weak under acidic conditions.^{14,39} When GSH was added into the releasing medium, the DOX release increased to 69% (pH 5.4 + GSH), 53.52% (pH 6.8 + GSH), and 45.21% (pH 7.4 + GSH). Therefore, the constructed MSNs-HA-11C12 drug loaded system has a dual stimulation response of pH and redox.

3.4. *In vitro* cellular cytotoxicity

The *in vitro* cytotoxicity of MSNs-HA-11C12 toward LoVo cells was analyzed by CCK8 assay (Fig. 5A). When the concentration of MSNs-HA-11C12 was between 1 and 50 $\mu\text{g mL}^{-1}$, the cell viabilities were close to 100%, and when increasing the concentration of MSNs-HA-11C12 up to 75 $\mu\text{g mL}^{-1}$ and 100 $\mu\text{g mL}^{-1}$, the cell viability still reached 97% and 81%, respectively. The prepared MSNs-HA-11C12 without the loading of DOX did not show obvious apoptosis toward LoVo cells after treatment for 48 h, which illustrated the good biocompatibility and safety of MSNs-HA-11C12.

The cytotoxic effects of DOX@MSNs-NH₂, DOX@MSNs-HA and DOX@MSNs-HA-11C12 at a tested concentration against LoVo cells for 48 h were also shown in Fig. 5B. The DOX loaded nanoparticles showed an obvious tendency to induce LoVo cell apoptosis in a dose-dependent manner. With free DOX as the control, it showed the highest cell killing effect compared with the drug loaded nanoparticles at all examined concentrations. Doses higher than 5 $\mu\text{g mL}^{-1}$ of free DOX showed significantly pronounced killing of LoVo cells, whereas at 20 $\mu\text{g mL}^{-1}$ free DOX for 48 h, the LoVo cell viability was only 7.3%. This might be due to the better diffusion effect of small molecules of DOX while increasing the probability of drug endocytosis in the *in vitro* cell experiment. More importantly, it was shown that DOX can likewise achieve highly efficient apoptosis toward CRC cells as a chemotherapeutic drug.⁴⁰ The LoVo cellular viability was 86.9% (1 $\mu\text{g mL}^{-1}$) and 45.6% (5 $\mu\text{g mL}^{-1}$) for DOX@MSNs-NH₂, and 66.2% (1 $\mu\text{g mL}^{-1}$) and 36.8% (5 $\mu\text{g mL}^{-1}$) for DOX@MSNs-HA after incubation with DOX@MSNs-NH₂ or DOX@MSNs-HA for 48 h. The results illustrate that MSNs-NH₂ modified by HA could significantly increase the apoptosis to LoVo cells resulting from the CD44 receptors of LoVo cell surface's targeting ability of the displayed HA on the MSNs-HA.




Fig. 5 (A) *In vitro* cell viability of LoVo incubated with different concentrations of MSNs-HA-11C12 for 48 h. (B) *In vitro* cell viability of LoVo cells incubated with different concentrations of DOX@MSNs-NH₂, DOX@MSNs-HA, DOX@MSNs-HA + free HA, DOX@MSNs-HA-11C12, and free DOX for 48 h. Error bars and standard deviations from three independent experiments.



When free HA was added to the DOX@MSNs-HA group as a competitive agent, the uptake of nanoparticles by cells was reduced due to free HA binding to the CD44 receptors of cell surfaces, which showed the reduction of LoVo cells apoptosis, and verified the targeting of HA in DOX@MSNs-HA. For example, the LoVo cellular viability ($5 \mu\text{g mL}^{-1}$) was 55.2% for DOX@MSNs-HA + free HA and 36.8% for DOX@MSNs-HA. At the same concentration, DOX@MSNs-HA-11C12 which was modified by two targeting molecules HA and 11C12 had the strongest apoptosis toward LoVo cells owing to the displayed HA and 11C12 targeting to the CD44 receptors and the proximal membrane end of CEA on the surface of CRC cells, respectively. When the DOX concentration was $20 \mu\text{g mL}^{-1}$, the LoVo cellular viability (8.9%) was obtained for DOX@MSNs-HA-11C12. This phenomenon indicated that the modification of HA and 11C12 increased the targeting of the MSNs drug delivery system toward LoVo cells, improved the binding between the drug delivery system and LoVo cells, and enhanced the probability of LoVo cell apoptosis.

3.5. *In vitro* cellular uptake

The LoVo cells were incubated with DOX, DOX@MSNs-NH₂, DOX@MSNs-HA, and DOX@MSNs-HA-11C12 for 2 h, respectively. Then, the internalization of DOX was assessed qualitatively by CLSM. DOX was employed as the fluorescent probe as it emits red fluorescence under a specified wavelength of excitation light.^{41,42} The cell nuclei were stained in blue by DAPI since it is a fluorescent dye that binds strongly to DNA. As shown in Fig. 6, DOX@MSNs-NH₂, DOX@MSNs-HA, and DOX@MSNs-HA-11C12 displayed obvious higher fluorescence intensity compared with free DOX, illustrating the amount of free DOX that was taken up by LoVo cells was minimal. The results were conflicted with the fact that free DOX led to the highest cell killing effect (Fig. 5), because the incubation time of free DOX and DOX loaded nanoparticles with LoVo cells were different in the cellular cytotoxicity and cellular uptake experiments. It was also suggested that the modified nanoparticles could transport more DOX to the cells in a shorter time. The fluorescence intensity trend was observed as follows: free DOX < DOX@MSNs-NH₂ < DOX@MSNs-HA < DOX@MSNs-HA-11C12. The DOX fluorescence of the cells treated with free DOX appeared in the cell due to molecular free diffusion. While the DOX fluorescence of the cells treated with DOX@MSNs-NH₂ was presented in the cell due to mainly enhanced permeability and the retention effect of the tumor. The increasing amount of DOX uptake from DOX@MSNs-HA-11C12 to DOX@MSNs-HA, higher than free DOX and DOX@MSNs-NH₂, results from the targeting ability of functional molecules, as DOX@MSNs-HA-11C12 was modified by both HA and 11C12. This is the first study to modify nanoparticles with HA and 11C12 in order to enhance the dual target ability. The DOX@MSNs-HA-11C12 possesses a dual targeting property resulting from the CD44 receptor targeting ability of HA and the targeting ability of 11C12 toward the proximal membrane end of CEA on the surface of CRC cells.




Fig. 6 CLSM images of LoVo cells after incubation with free DOX, DOX@MSNs-NH₂, DOX@MSNs-HA, and DOX@MSNs-HA-11C12 for 2 h.

The fluorescence spectrophotometer quantitatively analysed the uptake of free DOX, DOX@MSNs-NH₂, DOX@MSNs-HA, and DOX@MSNs-HA-11C12 by LoVo cells (Fig. 7). From the fluorescence intensity results, the uptake of DOX@MSNs-HA-11C12 by LoVo cells was the highest, followed by DOX@MSNs-HA, DOX@MSNs-NH₂, DOX, and the blank, which was consistent with the results of CLSM. For example, after incubating for 4 h, the fluorescence intensity was 4546 for DOX@MSNs-HA-11C12, 4278 for DOX@MSNs-HA, 1411 for DOX@MSNs-NH₂, and 570 for free DOX. Meanwhile, in a certain range, the uptake of free DOX, DOX@MSNs-NH₂, DOX@MSNs-HA, and DOX@MSNs-HA-11C12 by LoVo cells increased gradually with the extension of incubation time.




Fig. 7 Fluorescence spectrophotometer results of LoVo cells incubated with free DOX, DOX@MSNs-NH₂, DOX@MSNs-HA, and DOX@MSNs-HA-11C12 for 1 h, 2 h, and 4 h, respectively. Error bars and standard deviations from three independent experiments.



4. Conclusions

In this study, we developed a dual targeted drug delivery system modified by HA and nanobody 11C12 (MSNs-HA-11C12) to sustain and control the delivery of DOX for targeting CRC. The results of TGA, DLS, and FTIR demonstrated that HA and 11C12 were successfully functionalized on the surface of MSNs. The DOX-EE and DOX-DL of MSNs-HA-11C12 were 73.12% and 26.77%, respectively. *In vitro* release profiles illustrated that DOX@MSNs-HA-11C12 was a pH- and redox- responsive drug delivery system for DOX. *In vitro* cytotoxicity experiments exhibited that MSNs-HA-11C12 without loading of DOX showed good biocompatibility and safety toward LoVo cells. CLSM and fluorescence spectrophotometry showed that the increasing amount of DOX uptake from DOX@MSNs-HA-11C12 to DOX@MSNs-HA, higher than free DOX and DOX@MSNs-NH₂, results from the target ability of the functional molecule, as DOX@MSNs-HA-11C12 was modified by HA targeting for CD44 receptors and 11C12 targeting for the proximal membrane end of CEA on the surface of CRC cells. This is the first time that a drug delivery system has been combined with the targeting molecule HA and nanobody for CRC treatment, and this work provides new strategies for the clinical treatment of other major diseases.

Conflicts of interest

The authors declare no competing financial interests.

Acknowledgements

This work was supported by Shandong Energy Institute (SEI) [SEI I202144, SEI I202128].

References

- 1 L. H. Nguyen, A. Goel and D. C. Chung, *Gastroenterology*, 2020, **158**, 291–302.
- 2 H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, *Ca-Cancer J. Clin.*, 2021, **71**, 209–249.
- 3 E. M. Stoffel and C. C. Murphy, *Gastroenterology*, 2020, **158**, 341–353.
- 4 Z. Zhai, X. Yu, B. Yang, Y. Zhang, L. Zhang, X. Li and H. Sun, *Semin. Cell Dev. Biol.*, 2017, **64**, 107–115.
- 5 M. H. Chan and H. M. Lin, *Biomaterials*, 2015, **46**, 149–158.
- 6 W. Cheng, J. Nie, L. Xu, C. Liang, Y. Peng, G. Liu, T. Wang, L. Mei, L. Huang and X. Zeng, *ACS Appl. Mater. Interfaces*, 2017, **9**, 18462–18473.
- 7 Z. Li, J. C. Barnes, A. Bosoy, J. F. Stoddart and J. I. Zink, *Chem. Soc. Rev.*, 2012, **41**, 2590–2605.
- 8 E. Gullotti, J. Park and Y. Yeo, *Pharm. Res.*, 2013, **30**, 1956–1967.
- 9 D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit and R. Langer, *Nat. Nanotechnol.*, 2007, **2**, 751–760.
- 10 S. Wang, M. Cao, X. Deng, X. Xiao, Z. Yin, Q. Hu, Z. Zhou, F. Zhang, R. Zhang, Y. Wu, W. Sheng and Y. Zeng, *Adv. Healthcare Mater.*, 2015, **4**, 281–290.
- 11 C. W. Lin, K. Y. Lu, S. Y. Wang, H. W. Sung and F. L. Mi, *Acta Biomater.*, 2016, **35**, 280–292.
- 12 H. Ponta, L. Sherman and P. A. Herrlich, *Nat. Rev. Mol. Cell Biol.*, 2003, **4**, 33–45.
- 13 C. Chen, S. Zhao, A. Karnad and J. W. Freeman, *J. Hematol. Oncol.*, 2018, **11**, 64.
- 14 B. Gupta, B. K. Poudel, H. B. Ruttala, S. Regmi, S. Pathak, M. Gautam, S. G. Jin, J. H. Jeong, H. G. Choi, S. K. Ku, C. S. Yong and J. O. Kim, *Acta Biomater.*, 2018, **80**, 364–377.
- 15 S. Ogino, N. Nishida, R. Umemoto, M. Suzuki, M. Takeda, H. Terasawa, J. Kitayama, M. Matsumoto, H. Hayasaka, M. Miyasaka and I. Shimada, *Structure*, 2010, **18**, 649–656.
- 16 M. Ma, H. Chen, Y. Chen, K. Zhang, X. Wang, X. Cui and J. Shi, *J. Mater. Chem.*, 2012, **22**, 5615–5621.
- 17 M. Campos-da-Paz, J. G. Dórea, A. S. Galdino, Z. G. M. Lacava and M. de Fatima Menezes Almeida Santos, *Recent Pat. Biotechnol.*, 2018, **12**, 269–279.
- 18 M. Bacac, T. Fauti, J. Sam, S. Colombetti, T. Weinzierl, D. Ouaret, W. Bodmer, S. Lehmann, T. Hofer, R. J. Hosse, E. Moessner, O. Ast, P. Bruenker, S. Grau-Richards, T. Schaller, A. Seidl, C. Gerdes, M. Perro, V. Nicolini, N. Steinhoff, S. Dudal, S. Neumann, T. von Hirschheydt, C. Jaeger, J. Saro, V. Karanikas, C. Klein and P. Umaña, *Clin. Cancer Res.*, 2016, **22**, 3286–3297.
- 19 M. C. da Paz, M. F. Santos and C. M. Santos, *Int. J. Nanomed.*, 2012, **7**, 5271–5282.
- 20 M. A. Fernandes, J. O. Eloy, M. T. Luiz, S. Junior and M. Chorilli, *Colloids Surf., A*, 2021, **611**, 125806.
- 21 C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E. B. Songa, N. Bendahman and R. Hamers, *Nature*, 1993, **363**, 446–448.
- 22 S. Muyldermans, T. N. Baral, V. C. Retamozzo, P. De Baetselier, E. De Genst, J. Kinne, H. Leonhardt, S. Magez, V. K. Nguyen, H. Revets, U. Rothbauer, B. Stijlemans, S. Tillib, U. Wernery, L. Wyns, G. Hassanzadeh-Ghassabeh and D. Saerens, *Vet. Immunol. Immunopathol.*, 2009, **128**, 178–183.
- 23 M. Arbabi Ghahroudi, A. Desmyter, L. Wyns, R. Hamers and S. Muyldermans, *FEBS Lett.*, 1997, **414**, 521–526.
- 24 C. Sheridan, *Nat. Biotechnol.*, 2017, **35**, 1115–1117.
- 25 Q. Chen, Y. Zhou, J. Yu, W. Liu, F. Li, M. Xian, R. Nian, H. Song and D. Feng, *Protein Expression Purif.*, 2019, **155**, 43–47.
- 26 J. Lin, J. Yu, H. Wang, Y. Xu, F. Li, X. Chen, Y. Liang, J. Tang, L. Wu, Z. Zhou, C. Chen, M. Liu, X. Chun, R. Nian and H. Song, *Anal. Bioanal. Chem.*, 2020, **412**, 1723–1728.
- 27 J. Gu, W. Fan, A. Shimojima and T. Okubo, *Small*, 2007, **3**, 1740–1744.
- 28 N. Lang and A. Tuel, *Chem. Mater.*, 1966, **16**, 1961–1966.
- 29 Z. Bao, Y. Sun, K. Rai, X. Peng, S. Wang, R. Nian and M. Xian, *Biomater. Sci.*, 2018, **6**, 3042–3052.
- 30 X. Zeng, W. Tao, L. Mei, L. Huang, C. Tan and S.-S. Feng, *Biomaterials*, 2013, **34**, 6058–6067.
- 31 C. Tao, Y. Zhu, Y. Xu, M. Zhu, H. Morita and N. Hanagata, *Dalton Trans.*, 2014, **43**, 5142–5150.



- 32 L. S. Wang, L. C. Wu, S. Y. Lu, L. L. Chang, I. T. Teng, C. M. Yang and J. Ho, *ACS Nano*, 2010, **4**, 4371–4379.
- 33 J. Kim, J. E. Lee, J. Lee, Y. Jang, S. W. Kim, K. An, J. H. Yu and T. Hyeon, *Angew. Chem., Int. Ed.*, 2006, **45**, 4789–4793.
- 34 Q. Zhao, J. Liu, W. Zhu, C. Sun, D. Di, Y. Zhang, P. Wang, Z. Wang and S. Wang, *Acta Biomater.*, 2015, **23**, 147–156.
- 35 Z. Chen, Z. Li, Y. Lin, M. Yin, J. Ren and X. Qu, *Chemistry*, 2013, **19**, 1778–1783.
- 36 Y. Zhou, G. Quan, Q. Wu, X. Zhang, B. Niu, B. Wu, Y. Huang, X. Pan and C. Wu, *Acta Pharm. Sin. B*, 2018, **8**, 165–177.
- 37 L. Cai, P. Zhu, F. Huan, J. Wang, L. Zhou, H. Jiang, M. Ji and J. Chen, *Colloids Surf., B*, 2021, **205**, 111839.
- 38 M. Kim, D. Ki, Y. Na, H. Lee, J. Baek, J. Lee, H. Lee and C. Cho, *Pharmaceutics*, 2021, **13**, 184.
- 39 L. Chen, L. Li, L. Zhang, S. Xing, T. Wang, Y. A. Wang, C. Wang and Z. Su, *ACS Appl. Mater. Interfaces*, 2013, **5**, 7282–7290.
- 40 F. Muhammad, M. Guo, W. Qi, F. Sun, A. Wang, Y. Guo and G. Zhu, *J. Am. Chem. Soc.*, 2011, **133**, 8778–8781.
- 41 R. Zhang, C. Wu, X. Wang, S. Qian, B. Chen, X. Li, S. Gutmann and L. Gang, *Mater. Sci. Eng., C*, 2009, **29**, 1697–1701.
- 42 K. Dong, Z. Z. Zhao, J. Kang, L. R. Lin, W. T. Chen, J. X. Liu, X. L. Wu and T. L. Lu, *Int. J. Nanomed.*, 2020, **15**, 10285–10304.

